Association of interferon-γ and interleukin 10 genotypes and serum levels with partial clinical remission in type 1 diabetes

Clinical and Experimental Immunology

Volumn 145, Issue 3, 2006, Pages 480-484

  Alizadeh, B Z ^a,b,d,e   Hanifi Moghaddam, P ^a,c,d,e   Eerligh, P ^a,d,e   Van Der Slik, A R ^a,d,e   Kolb, H ^c   Kharagjitsingh, A V ^j,l   Arias, A M Pereira ^a,d,e,l   Ronkainen, M ^k,l   Knip, M ^a,d,e   Bonfanti, R ^f,l   Bonifacio, E ^f   Devendra, D ^g,l   Wilkin, T ^g   Giphart, M J ^a,d,e   Koeleman, B P C ^a,b,d,e   Nolsoe R ^h,l   Poulsen, T Mandrup ^h,i   Schloot, N C ^c   Roep, B O ^a,d,e  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY OF HELSINKI   (Finland)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g PENINSULA MEDICAL SCHOOL   (United Kingdom)

^h STENO DIABETES CENTER   (Denmark)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^k UNIVERSITY OF OULU   (Finland)

^l DIABMARKER Study Group

more..

Author keywords

Clinical remission; Disease marker; IFN ; IL 10; Prediction; Type 1 diabetes

Indexed keywords

GAMMA INTERFERON; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 10;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE MARKER; FEMALE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; INTERFERON GAMMA GENE; INTERFERON PRODUCTION; INTERLEUKIN 10 GENE; MALE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; TRANSCRIPTION REGULATION;

ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 1; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; REMISSION, SPONTANEOUS; SAMPLE SIZE;

EID: 33747392476     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2006.03172.x     Document Type: Article

References (18)

1. Hramiak IM, Dupre J, Finegood DT. Determinants of clinical remission in recent-onset IDDM. Diabetes Care 1993; 16:125-32.
2. Martin S, Pawlowski B, Greulich B, Ziegler AG, Mandrup-Poulsen T, Mahon J. Natural course of remission in IDDM during 1st yr after diagnosis. Diabetes Care 1992; 15:66-74.
3. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352:2598-608.
4. Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346:1692-8.
5. Hoppu S, Harkonen T, Ronkainen MS et al. IA-2 antibody isotypes and epitope specificity during the prediabetic process in children with HLA-conferred susceptibility to type I diabetes. Clin Exp Immunol 2006; 144:59-66.
6. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 1994; 331:1428-36.
7. Arif S, Tree TI, Astill TP et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004; 113:451-63.
8. Kallmann BA, Lampeter EF, Hanifi-Moghaddam P, Hawa M, Leslie RD, Kolb H. Cytokine secretion patterns in twins discordant for Type I diabetes. Diabetologia 1999; 42:1080-5.
9. Hanifi-Moghaddam P, Schloot NC, Kappler S, Seissler J, Kolb H. An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes 2003; 52:1137-42.
10. Pravica V, Asderakis A, Perrey C, Hajeer A, Sinnott PJ, Hutchinson IV. In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene. Eur J Immunogenet 1999; 26:1-3.
11. Eerligh P, Koeleman BP, Dudbridge F, Jan Bruining G, Roep BO, Giphart MJ. Functional genetic polymorphisms in cytokines and metabolic genes as additional genetic markers for susceptibility to develop type 1 diabetes. Genes Immun 2004; 5:36-40.
12. Gibson AW, Edberg JC, Wu J, Westendorp RG, Huizinga TW, Kimberly RP. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 2001; 166:3915-22.
13. Khoury MJ, Newill CA, Chase GA. Epidemiologic evaluation of screening for risk factors: application to genetic screening. Am J Public Health 1985; 75:1204-8.
14. Schloot NC, Hanifi-Moghaddam P, Goebel C et al. Serum IFN-gamma and IL-10 levels are associated with disease progression in non-obese diabetic mice. Diabetes Metab Res Rev 2002; 18:64-70.
15. Cardell SL. The natural killer T lymphocyte: a player in the complex regulation of autoimmune diabetes in non-obese diabetic mice. Clin Exp Immunol 2006; 143:194-202.
16. Ide A, Kawasaki E, Abiru N et al. Genetic association between interleukin-10 gene promoter region polymorphisms and type 1 diabetes age-at-onset. Hum Immunol 2002; 63:690-5.
17. Urcelay E, Santiago JL, de la Calle H, et al. Interleukin-10 polymorphisms in Spanish type 1 diabetes patients. Genes Immun 2004; 5:306-9.
18. Feutren G, Papoz L, Assan R et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986; 2:119-24.